About us

Ambys Medicines is working to fundamentally transform the lives of people suffering from severe liver diseases by creating breakthrough therapies capable of restoring liver function, preventing the progression of liver disease, and treating the devastating complications of liver failure.

We are pioneering multiple novel technologies — including liver cell therapy, liver reprogramming gene therapies, and liver-targeted drug therapies — to meet the urgent need for treatments that reverse disease progression across multiple liver diseases that are untreatable or poorly treated today.

MANAGEMENT TEAM

Founded by renowned experts in liver disease and regenerative medicine, Ambys Medicines has assembled a world-class team of cross-functional experts united in their mission to transform treatment for patients with serious liver disease.

INVESTORS & PARTNERS

Ambys Medicines is collaborating with top academic scientists and other partners to lead the fight against advanced liver disease and its complications. Ambys launched with committed funding of $140 million, including a $60 million Series A round funded by Third Rock Ventures and Takeda.

Third Rock Ventures is a leading healthcare venture firm focused on disruptive areas of science and medicine to discover, launch and build companies that make a dramatic difference in people’s lives. By combining scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, Third Rock Ventures nurtures bold ideas that translate into successful business enterprises.

Takeda Pharmaceutical Company Limited (TSE: 4502) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.